Design of the HPV-Automated Visual Evaluation (PAVE) Study: Validating a Novel Cervical Screening Strategy

  1. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
  2. ISGlobal, Barcelona, Spain
  3. University Chobanian and Avedisian School of Medicine/Boston Medical Center, Boston, MA, USA
  4. Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA
  5. Information Management Services Inc, 3901 Calverton Blvd Suite 200, Calverton, MD, USA
  6. Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA
  7. Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
  8. Westchester Medical Center/New York Medical College, Valhalla, NY, USA
  9. Feinberg School of Medicine at Northwestern University, Chicago, IL, USA
  10. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
  11. Harvard Graduate Program in Biophysics, Harvard Medical School, Harvard University, Cambridge, MA, USA
  12. Massachusetts Institute of Technology, Cambridge, MA, USA
  13. Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA
  14. University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a response from the authors (if available).

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Talía Malagón
    McGill University, Montreal, Canada
  • Senior Editor
    Eduardo Franco
    McGill University, Montreal, Canada

Reviewer #1 (Public Review):

Summary:

A description of a modern protocol for cervical screening that likely could be used in any country of the world, based on self-sampling, extended HPV genotyping and AI-assisted visual inspection - which is probably the best available combination today.

Strengths:

Modern, optimised protocol, designed for global use. Innovative.

Weaknesses:

The protocol is not clear. I could not even find how many women were going to be enrolled, the timelines of the study, the statistical methods ("comparing" is not statistics) or the power calculations.

Tables 2 and 3 are too schematic - surely the authors must have an approximate idea of what the actual numbers are behind the green, red and yellow colors.

Figure 1 comparing screening and vaccination is somewhat misleading. They screen 20 birth cohorts but vaccinate only 5 birth cohorts. Furthermore, the theoretical gains of screening has not really been attained in any country in practice. Modelling can be a difficult task and the commentary does not provide any detail on how to evaluate what was done. It just seems unnecessary to attack vaccination as a motivation on why screening needs to be modernised.

Reviewer #2 (Public Review):

Summary:

This manuscript describes the study protocol, structure and logic of the PAVE strategy. The PAVE study is a multicentric study to evaluate a novel cervical screen-triage-treat strategy for resource-limited settings as part of a global strategy to reduce cervical cancer burden. The PAVE strategy involves: 1) screening with self-sampled HPV testing; 2) triage of HPV-positive participants with a combination of extended genotyping and visual evaluation of the cervix assisted by deep-learning-based automated visual evaluation (AVE); and 3) treatment with thermal ablation or excision (Large Loop Excision of the Transformation Zone). The PAVE study has two phases: efficacy (2023-2024) and effectiveness (planned to begin in 2024-2025). The efficacy phase aims to refine and validate the screen-triage portion of the protocol. The effectiveness phase will examine implementation of the PAVE strategy into clinical practice.

Strengths and weaknesses:

The Pave Study develops and evaluates a novel strategy that combines HPV self-collection, that has been proven effective to increase screening coverage in different settings, with genotyping and Automated Visual Evaluation as triage. The proposed strategy combined three key innovations to improve an important step in the cervical cancer care continuum. If the strategy is effective it will contribute to enhancing cervical cancer prevention in low resource settings.

As the authors mentioned, despite the existence of effective preventive technologies (e.g., HPV vaccine and HPV test) translation of the HPV prevention methods has not yet occurred in many Low-Middle-Income Countries. So, in this context, new screen-triage-treat strategies are needed and if PAVE strategy were effective, it could be a landmark for cervical cancer prevention.

The PAVE Study is a solid and important study that is aimed to be carried out in nine countries and recruit tens of thousands of women. It is a study with a large and diverse sample that can provide useful information for the development of this new screen-triage-treat strategy. Another strength is the fact that the PAVE project is integrated into the screening activities placed in the selected countries that will allow to evaluate efficacy and effectiveness in real-word context.

The manuscript does not present results because its aim is to describe the study protocol, structure and logic of the PAVE strategy.

Phase 1 aims to evaluate the efficacy of the strategy. Methods are well described and are consistent with the study aims.

Phase 2 aims to evaluate the implementation of the PAVE strategy in clinical practice. The inclusion of implementation evaluation in this type of studies is an important milestone in the field of cervical cancer prevention. It has been shown that many strategies that have proven to be effective in controlled studies face barriers when they are implemented in real life. In that sense, the results of phase 2 are key to ensure the future implementation of the strategy.

However, some aspects of Phase 2 need to be clarified and extended. Although authors mentioned that implementation outcomes, such as acceptability and feasibility will be evaluated, more information is needed about method (i.e. qualitative/quantitative), data collection tools (i.e., survey, semi-structure interviews, focus groups, etc.) and frameworks that will be used to evaluate these implementation outcomes.

Reviewer #3 (Public Review):

Summary:

Despite being preventable and treatable, cervical cancer remains the second most common cause of cancer death globally. This cancer, and associated deaths, occur overwhelmingly in low- and middle-income countries (LMIC), reflecting a lack of access to vaccination, screening and treatment services. Cervical screening is the second pillar in the WHO strategy to eliminate cervical cancer as a public health problem and will be critical in delivering early gains in cervical cancer prevention as the impact of vaccination will not be realized for several decades. However, screening strategies implemented in high income countries are not feasible or affordable in LMICs. This ambitious multi-center study aims to address these issues by developing and systematically evaluating a novel approach to cervical screening. The approach, based on primary screening with self-collected specimens for HPV testing, is focused on optimizing triage of people in whom HPV is detected, so that sensitivity for the detection of pre-cancer and cancer is maximized while treatment of people without pre-cancer or cancer is minimized.

Strengths:

The triage proposed for this study builds on the authors' previously published work in designing the ScreenFire test to appropriately group the 13 detected genotypes into four channels and to develop automated visual evaluation (AVE) of images of the cervix, taken by health workers.

The move from mobile telephone devices to a dedicated device to acquire and evaluate images overcomes challenges previously encountered whereby updates of mobile phone models required retraining of the AVE algorithm.

The separation of the study into two phases, an efficacy phase in which screen positive people will be triaged and treated according to local standard of care and the performance of AVE will be evaluated against biopsy outcomes will be followed by the second phase in which the effectiveness, cost-effectiveness, feasibility and acceptability will be evaluated.

The setting in a range of low resource settings which are geographically well spread and reflective of where the global cancer burden is highest.

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation